Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 2 | Diabetology & Metabolic Syndrome

Fig. 2

From: Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study

Fig. 2

Participant flow during the trial. A total of 58 participants were enrolled, with 30 assigned to switch to oral semaglutide and 28 to continue their current DPP-4 inhibitors. Finally, 24 and 27 participants in the respective groups completed the 24-week study

Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us